European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT)
Titel:
European Post-Approval Safety Study (EU Pass) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including Second Primary Malignancies, in a Large Cohort of Patients (Pts) Treated With Lenalidomide (LEN), Thalidomide (THAL), and Bortezomib (BORT)
Auteur:
Gamberi, Barbara Hernandez, Miguel T. Berthou, Christian Tholouli, Eleni Zamagni, Elena Hajek, Roman Minnema, Monique Dimopoulos, Meletios Athanasios Caers, Jo Andersen, Niels Frost Andreasson, Bjorn Waage, Anders Crotty, Gerard Kueenburg, Elisabeth Rosettani, Barbara Di Micco, Antonio Bacon, Pamela Blau, Igor Wolfgang